Biotech Values

[DewDiligence]

Re: Iressa survival data by year-end:

I consider this bullish for OSIP. Normally, when an event-driven (a euphemism for death-driven) trial wraps up earlier than expected, it's bearish for the therapy being tested because it means that patients are not living as long as expected. Of course, it could be only the placebo patients who are dying early but, more likely, it's the Iressa patients.

What's bearish for Iressa competitively is of course bullish for Tarceva.

Happy Thanksgiving to all!